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Abstract.  Leukocyte activation is a complex process 
that involves multiple cross-regulated cell adhesion 
events. In this report,  we investigated the role of inter- 
cellular adhesion molecule-3 (ICAM-3), the third 
identified ligand for the/32 integrin leukocyte 
function-associated antigen-1  (LFA-1), in the regulation 
of leukocyte adhesion to ICAM-1, vascular cell adhe- 
sion molecule-1 (VCAM-1),  and the 38- and 80-kD 
fragments of fibronectin (FN40 and FN80). The ac- 
tivating anti-ICAM-3  HP2/19, but not other 
anti-ICAM-3  mAb, was able to enhance T  lympho- 
blast adhesion to these proteins when combined with 
very low doses of anti-CD3 mAb, which were unable 
by themselves to induce this phenomenon.  In contrast, 
anti-ICAM-1  mAb did not enhance T cell attachment 
to these substrata.  T cell adhesion to ICAM-1, 
VCAM-1,  FN40, and FN80 was specifically blocked by 
anti-LFA-1,  anti-VLAot4,  and anti-VLAa5  rnAb, 
respectively. The activating anti-ICAM-3  HP2/19 was 
also able to specifically enhance the VLA-4- and 
VLA-5-mediated binding of leukemic T Jurkat cells to 
VCAM-1,  FN40, and FN80, even in the absence of 
cooccupancy of the CD3-TcR complex. We also stud- 
ied the localization of ICAM-3, LFA-1, and the 
VLA/31  integrin,  by immunofluorescence microscopy, 
on cells interacting  with ICAM-1, VCAM-1  and FN80. 
We found that the anti-ICAM-3  HP2/19 mAb 
specifically promoted a dramatic change on the mor- 
phology of T  lymphoblasts when these cells were 
allowed to interact with those adhesion ligands.  Under 
these conditions,  it was observed that a large cell con- 
tact area from which an uropod-like structure (heading 
uropod) was projected toward the outer milieu.  How- 
ever, when T blasts were stimulated with other adhe- 
sion promoting agents as the activating anti-VLA/~l 
TS2/16 mAb or phorbol esters, this structure was not 
detected. The anti-ICAM-3  TP1/24 mAb was also un- 
able to induce this phenomenon.  Notably, a  striking 
cell redistribution of ICAM-3 was induced specifically 
by the HP2/19 mAb, but not by the other anti- 
ICAM-3 rnAb or the other adhesion promoting agents. 
Thus,  ICAM-3 was almost exclusively concentrated in 
the most distal portion of the heading uropod whereas 
either LFA-1 or the VLA/31  integrin were uniformly 
distributed all over the large contact area.  Moreover, 
this phenomenon was also observed when T cells were 
specifically stimulated with the HP2/19 mAb to inter- 
act with TNFo~-activated  endothelial cells. We found 
the localization of linear arrays of myosin within the 
heading uropod.  In contrast,  actin-based cytoskeleton 
presented a uniform distribution over the broad con- 
tact area with the substrate.  In addition,  butanedione 
monoxime, a  myosin-disrupting drug,  abolished both 
the morphological cell change and ICAM-3 clustering. 
Altogether, these results demonstrate that ICAM-3 has 
a  regulatory role on multiple pathways of T cell adhe- 
sion and morphology. 
T  rtE interactions  of cells with either other cells or with 
the extracellular  matrix,  have  been involved  in the 
regulation  of multiple physiologic processes. On leu- 
kocytes, the members of the Integrin,  Immunoglobulin,  and 
Selectin families of cell adhesion receptors appear to be the 
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major molecules involved  in those interactions  (Springer, 
1990; Hynes, 1992). Interestingly, the adhesion capability of 
Integrins can be regulated.  Most of the members of the inte- 
grin family which are expressed by leukocytes require an ac- 
tivation  step to  acquire  the ability  to  interact  with  their 
ligands. This activation process can be accomplished by cel- 
lular activation,  as described for the members of the/31,/32, 
and/33 integrins (Dustin and Springer,  1989; Shimizu et al., 
1990; Springer,  1990; Postigo et al.,  1991), or induced by 
the ligands  themselves,  as it occurs with the/33  integrin 
~i~3  (Duet al.,  1991). 
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very late  activation  antigen  (VLA)-4 ~ (o~4~1) and  VLA-5 
(ct5~1)  integrins  with several distinct sequences of human 
plasma fibronectin.  Thus,  VLA-5 recognizes the Arg-Gly- 
Asp sequence, while VLA-4 recognizes the CS1,  CS5, and 
H1  peptides  of  fibronectin  (FN)  (Wayner  et  al.,  1989; 
Garcfa-Pardo  et al.,  1990;  Mould and  Humphries,  1991; 
Mould et al., 1991). Several proteolytic fragments can be ob- 
tained  by trypsin digestion of FN.  Among  them,  the  38- 
(FN40) and 80-kD (FN80) fragments are recognized by the 
VLA-4 and VLA-5 integrins,  respectively (Wayner et al., 
1989;  Garcfa-Pardo et al.,  1990;  Yamada,  1991).  In addi- 
tion, VLA-4 interacts with a cell surface ligand termed vas- 
cular cell adhesion molecule (VCAM-1) (Elices et al., 1990), 
which belongs to the Immunoglobulin gene superfamily and 
has been shown to be expressed by cytokine-stimulated en- 
dothelial cells (Osborn et al.,  1989). VLA-4 and VLA-5 in- 
teraction with fibronectin as well as VLA-4/VCAM-1 inter- 
action  appear  to  be  essential  for  several  physiologic 
processes such as B lymphocyte maturation (Rolchin et al., 
1992),  lymphopoiesis (Williams et al.,  1991),  myogenesis 
(Rosen et al.,  1992), leukocyte extravasation to the sites of 
inflammation (Laff6n et al., 1991; Postigo et al.,  1992; Yed- 
hock et al., 1992), and T lymphocyte activation (Matsuyama 
et al.,  1989; Nojima et al.,  1990; Burkly et al.,  1991). 
Three members of the Immunoglobulin  superfamily, the 
intercellular  adhesion  molecule-I,  -2,  and  -3  (ICAM-1, 
ICAM-2,  and  ICAM-3)  have  been  described  as  counter- 
receptors for the lymphocyte function-associated antigen-1 
(LFA-1) integrin (Springer,  1990; Fawcett et al.,  1992; Vaz- 
eux et al.,  1992; Campanero et al.,  1993; De Fougerolles 
et al.,  1993). In contrast to ICAM-1 and ICAM-2, ICAM-3 
is exclusively expressed on cells of leukocyte lineage (De 
Fougerolles  and  Springer,  1992;  Acevedo et  al.,  1993). 
Moreover, ICAM-3 is the most abundantly expressed LFA-1 
counter-receptor  on  leukocytes  (De  Fougerolles  et  al., 
1993). 
We have recently shown that ICAM-3 participates in T cell 
activation and regulates the LFA-1/ICAM-1  adhesion path- 
way in  these cells  (Campanero  et al.,  1993;  Hern,~ndez- 
Caselles et al., 1993). We have herein studied the functional 
role of ICAM-3 on T cell adhesion. We have found that this 
molecule is also involved in the regulation of T cell binding 
to ICAM-1, VCAM-1, and fibronectin, as well as in the con- 
trol of cellular morphology. The relevance of these findings 
is discussed. 
Materials and Methods 
Antibodies, Protein Substrata, and Reagents 
The  anti-ICAM-3  HP2/19  and TP1/24,  anti-CDlla TSI/ll  and  TPI/40, 
anti-ICAM-1 RRI/1  and R6.5D6,  anti-CD29 TS2/16,  anti-CIM9d HP2/1, 
anti-CD49e  SAM-I,  and  anti-CD3  SPV-T3b  mAb have been described 
(Sfmchez-Madrid et al.,  1983,  1986;  Hemler et al.,  1984;  Spits et al., 
1985; Rothlein et al., 1986; Smith et al., 1988; Te Velde et al., 1988; Cam- 
panero et al., 1993).  SAM-1 and RRI/1 and R6.5D6 mAbs were a generous 
gift  of Dr.  C.  Figdor  (Netherland  Cancer  Institute,  Amsterdam,  The 
1. Abbreviations used in this paper: FN, fibronectin; HUVEC, human um- 
bilical vein endothelial cells; ICAM, intercellular adhesion molecule; LFA, 
lymphocyte function-associated antigen;  VCAM, vascular cell adhesion 
molecule; VLA, very late activation antigen. 
Netherlands) and R.  Rothlein (Boehringer Ingelheim, Ridgefleld, CT), 
respectively. MAb were purified from ascites fluid with protein A coupled 
to Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden). Anti-talin 
and anti-c~-actinin rabbit sera were a  generous gift of Dr.  K.  Burridge 
(University of North Carolina, Chapel Hill, NC). Anti-myosin rabbit poly- 
clonal serum was purchased from Sigma Chem.  Co.  (St.  Louis,  MO). 
Recombinant chimeric ICAM-1-Fc and recombinant soluble (rs) VCAM-1 
and endothelial leukocyte adhesion molecule-I (rsELAM-1) were kindly 
provided by Dr. A. Craig (John Radcliffe Hospital, Oxford, Great Britain) 
and R. Lobb (Biogen, Cambridge, MA), respectively. The tryptic 38- and 
80-kD fibronectin fragments were kindly provided by Dr. A. Garcfa-Pardo 
(Centro de Investigaciones Biol6gicas, Madrid, Spain). 
FITC-conjugated phalloidin, cytochalasin D, colchicine, and butanedi- 
one monoxime were purchased from Sigma Chem. Co. 
Cells and Cell Lines 
Human T lymphoblasts were prepared from peripheral blood mononuclear 
cells by treatment with phytohemagglutinin (PHA, 0.5%; Pharmacia Fine 
Chemicals) for 48 h. Cells were washed and cultured in RPMI 1640 (Flow 
Lab., Irvine, Scotland) containing 10% FCS (Flow Lab.) and 20 U/m11L-2. 
T lymphoblasts cultured by 7-12 d were typically used in all ~periments. 
T lymphoblasts and T cell clones have been extensively used to study both 
LFA-l-mediated cell adhesion and T cell activation (Cantrell et al., 1984; 
van Kooyk et al.,  1991; Dransfield et al., 1992;  Campanero et al.,  1993). 
The Jurkat T cell line was maintained in RPMI 1640 plus 10%  FCS. 
Human umbilical vein endothelial cells (HUVEC) were obtained as de- 
scribed  (Dejana  et  al.,  1987).  Briefly,  umbilical  vein was  cannulated, 
washed, and incubated with 0.1%  collagenase P  (Boehringer Mannheim 
GmbH, Mannheim, Germany) for 20 rain at 37°C. Cells were seeded into 
flasks and cultured in M199 medium (Flow Lab.) supplemented with 20% 
FCS, 50/~g/ml endothelial cell growth supplement, and 100/zg/ml heparin 
(Sigma Chem. Co.). Cells within two passages were used. Cells were split 
1:3 and detached with a solution of 0.05 % Trypsin and 0.02%  EDTA (Flow 
Lab.) before using. 
Cell Adhesion Assays 
Adhesion assays were essentially performed as previously described (Ar- 
royo et al., 1992).  Briefly, 50 ~l/well of  20 mM Tris-HCl, pH 8.0, contain- 
ing  FN  fragments,  recombinant  chimeric  ICAM-1-Fc,  rsVCAM-1,  or 
rsELAM-1,  were used to  coat 96-well  microtiter EtA  II-Linbro plates 
(Costar, Cambridge, MA) for 2 h at 37'C and then saturated with PBS con- 
taining 1% HSA for 30 rain at 37°C. Thereafter, plates were washed with 
PBS and either 2-3  x  105  (T lymphoblasts) or  1  ×  105  (Jurkat  cells) 
cells/well in 100/ti were added and centrifuged for 5 min at  10 g before 
an incubation at 37°C for 10-20 min. To quantify cell attachment, the plate 
was washed with RPMI containing 0.5% HSA, cells were fixed with a mix- 
ture of acetone/methanol 1:1 and dyed with violet crystal 0.5%. Then, ab- 
sorbance at 540 um was measured in an ELISA reader (LP400; Kallestad, 
Chaska, MN) and optical density was found to be a linear function of num- 
ber of  cells by a calibration curve (optical density vs. number of  cells). Total 
cellular input was calculated by spinning wells with original number of cell 
aliquots, staining, and measuring optical density. 
Immunofluorescence 
Immunofluorescence experiments were performed as previously described 
(S~chez-Mateos et al.,  1993).  Briefly,  2  x  10  ~ T lymphoblasts were in- 
cubated in flat-bottomed, 24-well plates (Costar Corp., Cambridge, MA) 
in a final volume of 500 #1 of complete medium on coverslips coated with 
40/zg/ml ICAM-1-Fc, 20 #g/ml FN80, or 10/zg/ml VCAM-1-FN-80.  For 
some experiments, HUVEC were grown on gelatin-coated coverslips and 
stimulated with 10 ng/ml TNFt~ for 16 h at 37°C; then, T lymphoblasts were 
incubated on these coverslips. MAb or their F(ab'): fragments were added 
at a final concentration of 1 pg/ml and cells were allowed to settle in a cell 
incubator at 37°C and 5% CO2 atmosphere; after 30 min cells were fixed 
with 3.7% formaldehyde in PBS for 10 min at room temperature and rinsed 
in TBS (TBS:  50 mM Tris-HC1, pH 7.6, 150 mM NaCI, 0.1% NAN3). To 
directly visualize the stimulatory mAb, cells were stained with a 1:50 dilu- 
tion of an FITC-labeled rabbit F(ab')2 anti-mouse IgG (Pierce, Rockford, 
IL) as a secondary antibody. For double label studies, after directly staining 
the stimulatory.mAb with FITC-secondary antibody, cells were saturated 
with 10%  nonspecific mouse serum in TBS. Then, cells were incubated 
with 5/~g/ml biotinylated mAb to other proteins, followed by washing and 
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Figure  L  ICAM-3-mediated 
c: ELAM-1  induction of cell adhesion to 
endothelial  cell  membrane 
proteins. T lymphoblasts were 
pretreated for 30 min at 4°C 
with a combination of differ- 
ent doses of the anti-CD3 T3b 
mAb with either RPMI (e), 
HP2/19  (m),  TPI/24  (A) (A, 
-  B,  and  C),  RRI/1  (o),  or 
--II  ~  .......  t  .......  .,  o.ool  O.Ol  o.1  R6.5D6  ([~) mAbs (B). Next, 
10  #g/m]  sheep  anti-mouse 
IgG  was  added,  as  cross- 
linker,  for  10  min  at  4°C. 
Adhesion to micmtiter wells coated with 20 #g/ml ICAM-1-Fc (A), 5 #g/mi rsVCAM-I  (B), or 20 #g/ml rsELAM-1 (C) was quantified 
after 10 min of incubation at 37°C.  Arithmetic mean +SD of five experiments run by duplicate are shown. Adhesion to albumin-coated 
wells was always lower than 5 %. 
labeling with TRITC-avidin D (Vector Labs., Inc., Burlingame, CA) for 
30 min, washed with TBS and incubated with a biotinylated anti-avidin 
(Vector Labs.,  Inc.)  for  30  min.  Finally,  a  fourth incubation with 
TRITC-avidin D for 30 min was done. For staining of  cytoskeletal  proteins, 
cells were permeabilized with 0.2% Triton X-100 in TBS for 3 min. The 
secondary antibodies used were: RITC-goat anti-mouse  IgG, affinity- 
purified and cross-species adsorbed, and FITC-donkey anti-rabbit IgG 
(Chemicon Intl. Inc., Teruecula, CA). Polymerized actin was stained with 
6.6 #M FITC-phalloidin. The ceils were observed using a Nikon Labo- 
phot-2 photomicroscope with a 100  x  oil immersion objective and pho- 
tographed on either ektachrome 400 (color pictures) or TMAX 400 (black 
and white) film (Kodak). The latter was processed to 800-1600 ASA with 
TMAX developer (Kodak). Where indicated, red and green fluorescence 
was photographed on the same frame and, in some cases, we were com- 
pelled to move the focus in order to show both colors in focus. 
Results 
Regulation of[31 and f32 Integrin-mediated Cellular 
Interactions through ICAM-3 
We have recently shown that LFA-1/ICAM-1 interaction can 
be regulated through ICAM-3 (Campanero et al., 1993). We 
have now tested the possibility that ICAM-3 could also regu- 
late the T cell binding to other endothelial  cell adhesion mol- 
ecules as VCAM-1  and  ELAM-1.  As shown  in Fig.  1,  the 
anti-ICAM-3 HP2/19 mAb was able to enhance T  lympho- 
blast attachment to both ICAM-1 and VCAM-1, but not to 
ELAM-1;  this  effect  was  observed  only  when  the  anti- 
ICAM-3 mAb was combined with very low doses of anti- 
CD3 mAb, which were unable by themselves to induce this 
effect. When we used an anti-ICAM-3 mAb of identical Ig 
subclass and comparable affinity but directed against another 
different epitope (TP1/24), or anti-ICAM-1 mAbs, no effect 
was  detected  (Fig.  1).  ICAM-3-mediated  increased  cell 
binding to ICAM-1 and VCAM-1 was specifically inhibited 
by mAbs to the  LFA-1 and  VLA-4 integrins,  respectively 
(Fig. 2). Therefore, these results show that ICAM-3 is capa- 
ble to regulate the interaction of LFA-1 and VLA-4 with their 
respective endothelial cell counter-receptors. 
Since it has been described that VLA-4 interacts with the 
38-kD fibronectin fragment containing CS-1 (Wayner et al., 
1989), we tested the possibility that ICAM-3 could also regu- 
late this interaction.  As shown  in Fig.  3,  the anti-ICAM-3 
HP2/19  mAb  enhanced  the  VLA-4-mediated  T  lympho- 
blast adhesion to this fragment. Moreover, we have obtained 
evidence suggesting that ICAM-3 is also capable to regulate 
the VLA-5-mediated cell adhesion to its ligand. Thus,  the 
HP2/19 mAb was able to enhance T  lymphoblast adhesion 
to the 80-kD FN fragment containing the Arg-Gly-Asp  pep- 
tide,  and  this  event  was  specifically blocked by  the  anti- 
VLAc~5 SAM-1 mAb (Fig.  3).  However, the anti-ICAM-3 
TP1/24, as well as the anti-ICAM-1 RR1/1  and R6.5D6 mAb 
failed to enhance cell adhesion to both FN fragments (Fig. 
3). In addition, cell binding to fibrinogen was not enhanced 
by the anti-ICAM-3 HP2/19  mAb (data not shown). 
When  the  Jurkat  T  cell  line  was  stimulated  with  the 
anti-ICAM-3 HP2/19 mAb in the absence of anti-CD3 mAb, 
a  dramatic  increase  in  cell  adhesion  to  either  VCAM-1, 
FN40, or FN80, but not to ELAM-1 or fibrinogen, was ob- 
served (Fig. 4, and data not shown). Moreover, these effects 
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Figure 3. Induction of T cell adhesion to fibronectin fragments by ICAM-3. T lymphoblasts were pretreated  for 30 min at 4°C with a combi- 
nation of different doses of the anti-CD3 T3b mAb with either RPMI (e), HP2/19 (m), TP1/24 (a), RR1/1 (o), or R6.5D6 (c3) mAbs (.4 
and C). Next,  10 #g/ml sheep anti-mouse IgG was added, as cross-linker,  for 10 rain at 4°C. Cells activated with the anti-ICAM-3 antibody 
HP2/19 were subjected  to integrin blockade (B and D). To this end, after cell treatment with the cross-linker agent, cells were incubated 
for additional  15 rain at 4°C with either RPMI (-), HP2/1 (o), or SAM-1 (,t) mAbs. In B and D cell treatment with no additional  stimulus 
to anti-CD3  mAb is also shown (e). Adhesion to microtiter wells coated with either 5 #g/ml FN40 (.4 and B) or FNS0 (C and D) was 
quantified after 10 min of incubation  at 37°C. Arithmetic mean +SD of four separate  experiments  run by duplicate are shown.  Adhesion 
to albumin-  or fibrinogen-coated  wells was always lower than 5 %. 
were  specifically  blocked  by  either  anti-VLAa4  HP2/1 
(VCAM-1  and  FN40)  or the  anti-VLAa5  SAM-1  (FN80) 
mAb (Fig. 4).  These results strongly suggest that ICAM-3 
is able to transduce stimulatory signals in T ceils even in the 
absence of CD3-TcR occupancy. 
ICAM-3 Redistribution During T Cell Attachment to 
Different Adhesion Ligands 
We have performed double immunofluorescence analysis to 
investigate the distribution of ICAM-3 when cells were in- 
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Figure 4.  ICAM-3-mediated induction of Jurkat cell adhesion to 
VCAM-1 and  fibroneetin fragments in the absence of CD3-TcR 
stimulation. Jurkat cells were pretreated for 30 min at 4°C with 
different mAbs. Adhesion to microtiter wells coated with 5/zg/ml 
of either rsVCAM-1, FN40, or FN80 was quantified after 7 min of 
incubation at 37°C. Arithmetic mean +SD of five separate experi- 
ments  run  by  duplicate  are  shown. Adhesion  to  albumin-  or 
fibrinogen-coated wells was always lower than 5 %. 
duced to interact with immobilized ligands for/31 and/32 
integrins.  Very  interestingly,  when  T  lymphoblasts  were 
stimulated with the anti-ICAM-3 HP2/19 rnAb and allowed 
to  interact  with  ICAM-l-coated  coverslips,  a  dramatic 
change on T  cell morphology was  observed: most of the 
mAb-treated cells formed a large flattened contact area from 
which  an  uropod-like  structure  (hereafter designated  as 
heading uropod), where ICAM-3 was located, was projected 
towards the medium (Fig. 5 A). The ICAM-3 redistribution 
to the uropod was even more pronounced when activating 
conditions of coengagement of ICAM-3 and CD3-TcR were 
used (data not shown). However, this structure was not de- 
tected on mAb-untreated cells, and ICAM-3 was found uni- 
formly distributed on the cell surface (Fig. 5J). Staining of 
the LFA-1 integrin on both conditions showed a uniform cell 
distribution  on  the  large  contact  area  with  the  ICAM- 
1-coated surface (Fig. 5, B and K). A completely rounded 
morphology was observed when T blasts stimulated with the 
HP2/19 mAb were settled on BSA instead of ICAM-1  (data 
not shown). 
Double exposure for ICAM-3 and LFA-1 fluorescence on 
the same cells was taken in the same photographs in order 
to compare the distribution of LFA-1 and ICAM-3 on ceils 
interacting with ICAM-1.  Fig. 5 C clearly shows that LFA-1 
(red fluorescence) and ICAM-3 (green fluorescence) local- 
ized to different areas on the same cells upon T lymphoblast 
stimulation with the anti-ICAM-3 HP2/19 mAb: LFA-1 uni- 
formly distributed all over the large flattened contact area 
whereas ICAM-3 selectively decorated the heading uropod. 
In contrast, on unstimulated cells, LFA-1 and ICAM-3 dis- 
played a completely overlapping pattern of staining (orange 
color) (Fig. 5 L). Next, the distribution of ICAM-3 and the 
131 integrin was analyzed when T blasts were allowed to settle 
on either VCAM-1 or FNS0. The appearance of the heading 
uropod and ICAM-3 redistribution to this projection was ob- 
served in HP2/19 mAb-treated ceils (Fig. 5, D and G), but 
not on unstimulated T blasts (data not shown). In contrast, 
the/31 integrin was uniformly distributed over the large con- 
tact area with either the VCAM-1- or the FN80-coated sur- 
faces on both treated and mAb untreated T blasts (Fig. 5, E 
and H, and data not shown). Double exposure for ICAM-3 
and  /31  integrin  fluorescence  on  the  same  cells  clearly 
demonstrated that both molecules localized to different areas 
when these cells were interacting with VCAM-1  or FN80 
(Fig. 5, F  and I). 
Other stimuli,  as phorbol esters or the regulatory anti- 
VLAfll TS2/16 mAb, have previously been described to en- 
hance integrin-mediated cell adhesion to ICAM-1, VCAM-1, 
and FN (Dustin and Springer,  1989; Arroyo et al.,  1992). 
However,  the  appearance  of  the  heading  uropod  was 
specifically induced by the anti-ICAM-3 HP2/19. When T 
blasts were stimulated to interact with FN80 with the anti- 
VLAfll TS2/16 mAb or PMA, the heading uropod and the 
ICAM-3 redistribution were not observed (Fig. 6, C and D). 
Moreover,  ICAM-3-mediated  change  of  morphology  is 
epitope-specific since the other anti-ICAM-3 TP1/24 mAb, 
which is directed against a different epitope, failed to en- 
hance T cell adhesion, and it had no effect on these events 
(Fig. 6 B). Moreover, the latter mAb also failed to induce 
cell clustering of ICAM-3 (Fig. 6 B). Virtually all ICAM-3 
molecules  appeared  to be  sequestered in  the  uropod,  as 
demonstrated with cells treated with the activating HP2/19 
mAb,  and  then  stained  with  the  TP1/24  mAb  (data  not 
shown). 
ICAM-3 Redistribution During T Cell Interaction with 
Endothelial Cells 
To explore the possible in vivo relevance of ICAM-3-medi- 
ated induction of the heading uropod, we tested the ability 
of ICAM-3  to  stimulate  the  appearance of this  structure 
when T cells interact with endothelial cells. Human umbili- 
cal vein endothelial cells stimulated for 16 h with TNFot ex- 
press  both  ICAM-1  and  VCAM-1.  When  T  lymphoblasts 
were stimulated to interact with these endothelial cells with 
the anti-ICAM-3 HP2/19 mAb, the heading uropod and the 
ICAM-3 redistribution were clearly observed (Fig. 7 A). In 
contrast, the anti-ICAM-3 TP1/24 mAb was unable to in- 
duce  the  appearance  of the  heading  uropod  or  ICAM-3 
clustering (Fig. 7 B).  Moreover, phorbol esters also failed 
to induce both phenomena (Fig. 7  C). 
Campanero et al. ICAM-3-mediated Regulation of Cell Adhesion  871 Figure 5. Cellular localization of ICAM-3 and LFA-1 during T lymphoblast attachment to ICAM-1, VCAM-1, and FN80. T lymphoblasts 
were allowed to bind to coverslips coated with either 40/ttg/ml ICAM-1-Fc (A-C  and J-L), 10 #g/ml rsVCAM-1 (D-F), or 20/~g/ml FNS0 
(G-l) for 30 min at 37"C either in the presence (A-I) or absence (J-L) of the anti-ICAM-3  HP2/19 mAb. Then, fixed cells were double 
stained for ICAM-3 (A, D, G, and J) and LFA-1 (B and K) or VLAB1 (E and H) as described in Materials and Methods. In C, F,, L and 
L, red and green fluorescence was photographed  on the same frame by double exposure. The heading uropod and the cell contact area 
with the substratum were indeed in a distinct plane of focus. Bar, 10 tim. 
Cytoskeletal Reorganization  during ICAM-3 Regulated 
T Cell Morphological Changes 
To investigate the nature of the cytoplasmic interactions that 
drive ICAM-3  into  the  uropod  region,  the  localization  of 
f-actin and  various cytoskeletal proteins  was observed by 
fluorescence microscopy on ICAM-3-induced T cells adher- 
ing  to  FN80  (Fig.  8).  F-actin  was  present  through  the 
cytoplasm of the  cells,  but brighter  fluorescence was de- 
tected in the area of contact with the substrate (Fig.  8 A). 
Three other cytoskeletal proteins, talin, ceactinin (Fig. 8, B 
and C), and vinculin (not shown) demonstrated no preferen- 
tial  distribution  to  the  cell  uropod,  where  ICAM-3  was 
specifically concentrated (Fig. 8, E, F, and G), and similarly 
to f-actin, they displayed more pronounced fluorescence at 
the trailing membrane. 
The Journal of Cell Biology, Volume 127,  1994  872 Figure 6.  ICAM-3 but not other pro-adhesive stimuli specifically induces ICAM-3 relocation and the raising of the heading uropod. T 
lymphoblasts were allowed to bind to FNS0-coated coverslips (20/zg/ml)  for 30 min at 37°C in the presence of 5/~g/ml HP2/19 mAb 
(A), TP1/24 mAb (B), TS2/16 mAb (C), or 20 ng/ml PMA (D). Then fixed cells were stained for ICAM-3, as described in Materials 
and Methods, by using biotinylated anti-ICAM-3 TP1/24 mAb. Bar, 10 am. 
Actin polymerization contributes to the protrusion of cell 
margins  such as lamellipodia, but recent reports have de- 
scribed forms of cell protrusion that may instead be driven 
by myosin (Conrad et al.,  1993; Cramer et al.,  1994). Fig. 
8 D shows the asymmetric distribution of myosin during cell 
adhesion to FN80 induced with the activating anti-ICAM-3 
HP2/19 mAb. Cell uropods contained linear arrays of myo- 
sin,  while a punctate distribution was observed uniformly 
through the rest of the cytoplasm. 
To further investigate the involvement of  the myosin motor 
in the generation of the cell uropod and ICAM-3 reorganiza- 
tion,  we  used  the  myosin-disrupting  drug  butanedione 
monoxime (Cramer  et  al.,  1994).  All  cells  treated  with 
butanedione monoxime acquired a  spherical  morphology 
with a uniform distribution of ICAM-3 (Fig. 9 B). However, 
cell attachment to FNS0 was not affected by this treatment 
(Fig.  9 B, and data not shown). In contrast, disruption of 
microtubules with colchicine did not affect the polarization 
of ICAM-3 (Fig. 9  C). As expected, treatment of the cells 
with a  microfilament disrupting  element, cytochalasin D, 
resulted  in  a  complete  inhibition  of  cell  adhesion  (not 
shown). 
Discussion 
In this study, we have shown that ICAM-3 is a regulatory 
molecule that modulates/31 and ~52 integrin-mediated T cell 
binding to endothelial cell surface molecules, as  ICAM-1 
and VCAM-1, and to ECM components as fibronectin. In ad- 
dition, ICAM-3 distribution on the cell surface and T lym- 
phoblast morphology were dramatically modified upon cell 
stimulation through ICAM-3. 
It has been considered that integrins have an active func- 
tional role in cell activation, whereas their ligands do not. 
Thus, integrin ligands apparently only support cell attach- 
ment, whereas integrins display a more dynamic role. As a 
consequence of the interaction with their ligands, integrins 
transduce signals to the inside of cells, leading to changes 
in the cellular behavior. For instance, costimulatory signals 
are generated in T cells after LFA-1- and VLA-4-mediated 
Campanero et al.  ICAM-3-mediated Regulation  of Cell Adhesion  873 Figure 7. Regulation of  ICAM-3 relocation and raising of  the heading uropod on T cells that interact with endothelial cells. Human umbilical 
vein endothelial cells were stimulated with  10 ng/ml TNFc~ for 16 h at 37°C. Then,  T lymphoblasts were allowed to bind to coverslips 
coated with these cells for 30 min at 37°C in the presence of either medium alone (D) or any of  the following stimuli: 5 t~g/ml  anti-ICAM-3 
HP2/19 (A), TP1/24 mAb (B), or 20 ng/ml PMA (C). Then, fixed cells were stained for ICAM-3, as described in Materials and Methods, 
either by addition of FITC-labeled anti-mouse IgG (A and B) or by using biotinylated anti-ICAM-3  mAb (C and D). Endothelial cells 
displayed a basal fluorescence,  even though they were not specifically stained,  that allowed us to photograph  them (F). Bar, 10 ~tm. 
interactions with ICAM-1 and VCAM-1  (Burkly et al., 1991; 
van Seventer et al.,  1991; Hermindez-Caselles et al.,  1993). 
In  contrast,  no  evidence  exists  regarding  ICAM-1-  and 
VCAM-l-mediated stimulation of endothelial cells upon this 
interaction.  Interestingly,  we  have herewith  demonstrated 
that ICAM-3, the third identified counter-receptor for the leu- 
kocyte integrin LFA-1, is also a regulatory molecule able to 
modulate  both  cell  binding  to  different  proteins  and  cell 
morphology. These results suggest that other integrin coun- 
terreceptors  could also  have an  active functional  role.  In 
this regard, the absence of a regulatory role for ICAM-1 in 
our  system might be due  to the particular ICAM-1 mAbs 
employed. 
Stimuli that activate T lymphocytes, such as phorbol esters 
or antibodies against the CD3-TcR complex or the CD2 anti- 
gen, also activate the integrins expressed on the cell surface 
(Springer,  1990).  In addition,  the/31,  132, and/33  integrins 
can be activated upon binding of regulatory mAbs to these 
integrins (Gulino et al.,  1990;  van Kooyk et al.,  1991;  Ar- 
royo et al.,  1992;  Robinson et al.,  1992).  The mechanism 
responsible for the regulation of integrins by ICAM-3 likely 
involves cell activation since this phenomenon has been ob- 
served upon cell trealanent with the stimulatory anti-ICAM-3 
HP2/19 mAb (Campanero et al., 1993; Hern~dez-Caselles 
et al.,  1993). In addition, since regulation through ICAM-3 
of LFA-1, VLA-4, and VLA-5 activity seems to be due to T 
cell activation,  we can expect that additional  integrins on 
these cells are also regulated through  this LFA-1 counter- 
receptor. 
Activation of T lymphocytes with a wide number of stimuli 
involves the rise of intracellular calcium levels and/or PKC 
activation. It has recently been reported that mAb directed 
to certain epitopes of ICAM-3, when crosslinked with see* 
ond anti-Ig antibodies, induce a rise in intracellular calcium 
concentrations (Juan et al.,  1994).  However, when we ana- 
lyzed the possibility that mAb engagement of ICAM-3 could 
induce these intracellular events, no increase of intracellular 
calcium levels was observed upon anti-ICAM-3 cell treat- 
ment (our unpublished observations). Our previous results 
showing that the expression of the AIM/CD69 activation an- 
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orescence staining of  ICAM-3 
and cytoskeletal proteins on T 
lymphoblasts. Cells were in- 
duced  to  adhere  on  FN80 
for 30 rain at 37"C by using 
the  activating anti-ICAM-3 
HP2/19 mAb. After fixation, 
ICAM-3 was detected directly 
with  rhodamine-eonjugated 
goat  F(ab')2 anti-mouse  Ig 
(E-H). Cytoskeletal proteins 
in the same cells were detected 
after  permeabilization  with 
FITC-conjugated phalloidin to 
stain  filamentous  actin  (A), 
and with rabbit antisera against 
c~-actinin (B), talin  (C), and 
myosin (D) followed  by FFIC- 
conjugated  donkey  F(ab')2 
anti-rabbit  Ig. Bar, 10/~m. 
tigen on T lymphocytes could be induced upon cell treatment 
with the anti-ICAM-3 HP2/19 mAb (Hern,-tndez-Caselles et 
al.,  1993) strongly suggest that PKC activation could be in- 
volved in ICAM-3-mediated cellular responses. AIM/CD69 
is an inducible cell surface molecule whose expression on T 
lymphocytes is dependent on the activation of PKC (Cebri~in 
et al.,  1989). However, no conclusive results could be ob- 
tained on the putative involvement of this intracellular sig- 
naling pathway during ICAM-3-mediated regulation of cell 
binding to fibronectin by using PKC inhibitors as Staurospo- 
rine and H7 (our unpublished observations). Interestingly 
enough, recent evidence demonstrate the induction of tyro- 
sine phosphorylation of  different protein substrates in T cells 
by antibody engagement of ICAM-3 molecule (Arroyo et al., 
1994;  Juan et al.,  1994).  Moreover, the CD45  leukocyte 
tyrosine phosphatase appears to be involved in the regulation 
of ICAM-3-mediated  signaling  and  cell-cell  interactions 
(Arroyo et al.,  1994). 
We have reported that phorbol esters as well as the activat- 
ing  anti-ICAM-3  HP2/19 and  anti-VLA-/~l  TS2/16 mAb, 
regulate  leukocyte binding  to endothelial cells  and  ECM 
components (Arroyo et al.,  1992; and this report). Interest- 
Campanero et al. lCAM-3-mediated Regulation of Cell Adhesion  875 Figure 9. Effect of  the myosin-disrupting drug butanedione monox- 
ime on cell distribution of ICAM-3. Cells were induced to adhere 
on FN80 with the activating anti-ICAM-3 HP2/19 mAb, in the ab- 
sence (A) or in the presence of 10 mM butanedione monoxime (B), 
and  10 #M colchicine (C).  Cells were fixed and ICAM-3 was 
directly  visualized by rhodamine-conjugated F(ab'h  anti-mouse 
Ig. Bar,  10 #m. 
ingly, these stimuli differ in their ability to promote changes 
on the cellular morphology. ICAM-3 seems to be unique for 
stimulating the generation of the heading uropod. Both phor- 
bol esters and the anti-VLA-ffl TS2/16 mAb also induced 
cell spreading on ICAM-1 and VCAM-1 (Arroyo et al., 1992; 
Siinchez-Mataeos et al.,  1993), but the heading uropod was 
not detected. The recruitment of ICAM-3 to the uropod was 
observed on both T blast and Jurkat cells by engagement of 
ICAM-3 with the activating antibody without further cross- 
linking, as well as by coengagement of ICAM-3 and CD3- 
TcR (unpublished observations). Hence, both the raising of 
the  heading  uropod  and  ICAM-3  redistribution might be 
early events  in  the  cellular activation cascade  since both 
phenomena are observed under activating as well as under 
nonactivating conditions. In addition, clustering of ICAM-3 
and uropod generation are epitope-specific since an anti- 
ICAM-3  mAb  of  identical  Ig  isotype  and  comparable 
affinity, but directed against a different epitope, was not able 
to induce any of  either events. Interestingly, this phenomenon 
also took place when T cells were stimulated through ICAM-3 
to  interact with  endothelial cells  instead of purified pro- 
teins. In this regard, it has been reported that lymphocyte in- 
teractions with endothelial cells induced pseudopod forma- 
tion; the adhesion molecules CD2, CIM4, and L-selectin, 
but not LFA-1, were redistributed to this structure (Rosen- 
man et al.,  1993). 
The heading uropod may have a functional role and might 
be essential for the recruitment of  other leukocytes to inflam- 
matory foci because: (a) it is very well exposed since it is 
projected towards the outer milieu outgoing from the flat- 
tened  cellular  area  in  contact  with  the  substratum;  (b) 
ICAM-3 is highly concentrated there, thus facilitating LFA- 
1-mediated interaction of other leukocytes; and (c) we have 
previously shown that on small cell aggregates, T lympho- 
cytes come in contact through a uropod where ICAM-3 is 
accumulated (Campanero et al.,  1993). In good agreement, 
it has been postulated that a good exposure of the L-Selectin 
on neutrophils  facilitates its  interaction with  its  counter- 
receptor on endothelial cells (Picker et al.,  1991). In addi- 
tion, the local clustering of the leukocyte integrin Mac-1 or 
its ligand iC3b has been shown to facilitate their mutual in- 
teraction (Detmers et al., 1987; Hermanowski-Vosatka et al., 
1988). 
Another LFA-1 counter-receptor, ICAM-1,  has previously 
been reported to be redistributed on the cell surface of JY 
cells to an uropod-like structure that apparently interacts 
with LFA-l-coated surfaces (Dustin et al., 1992). Therefore, 
relocation of ICAMs to adhesive cellular areas seems to be 
a common characteristic of ICAMs. This similarity suggests 
that ICAM-1  and ICAM-3 might share common features on 
their cytoplasmic tails that would enable them to interact 
with the same  set of cytoskeletal proteins.  However, this 
does not appear to be the case because we have previously 
shown that ICAM-3 and ICAM-1  localized to different cell 
areas  on cell aggregates  induced through ICAM-3  (Cam- 
panero et al.,  1993). 
In the same regard, it has been previously reported that the 
cytoplasmic tail  of ICAM-1  interacts  with  the  actin-con- 
taining cytoskeleton and ~x-actinin (CatiOn et al.,  1992). 
In contrast,  ICAM-3  colocalizes neither with major actin 
concentrations in the cell nor with three other cytoskeletal 
focal adhesion proteins, talin, ot-actinin, and vinculin. Actin- 
based cytoskeleton appeared to be more concentrated in the 
broad area of contact with the substrate most distant from 
the cell uropod. Interestingly enough, the presence of linear 
arrays of myosin within the uropod region supports a role for 
myosin motor in both driving ICAM-3 towards the uropod 
and in the generation of this cellular structure. Accordingly, 
a myosin-disrupting drug completely abolished both events. 
These findings are in good agreement with previous reports 
suggesting that myosin mediates membrane motility in Dyc- 
tiostelium, Swiss 3T3 fibroblasts and the dorsal lip in Dro- 
sophila (Cramer et al.,  1994; Fath and Burgess,  1994). 
There is "cross-talk" between leukocyte and integrin acti- 
vation, since each process is involved in the regulation of the 
other. Thus, leukocyte activation leads to integrin molecules 
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on the other hand, ligand binding by integrins contributes to 
leukocyte activation. Our results suggest that ICAM-3 has an 
essential role in this cross-talk. In this regard, we have previ- 
ously shown that T cell activation enhances LFA-l-mediated 
T  cell  binding  to  ICAM-3  (Campanero  et  al.,  1993). 
Herewith, we have shown that engagement of ICAM-3 with 
mAb enhances the integrin-mediated binding to components 
of endothelial cells (ICAM-1 and VCAM-1) and extracellular 
matrix (fibronectin). In addition, it has been reported that ac- 
tivation of T lymphocytes through the CD3-TcR complex is 
markedly enhanced by  integrin-mediated adhesion events 
(Matsuyama et al., 1989; Burkly et al., 1991; van Seventer 
et al., 1991; Hermtndez-Caselles et al., 1993), as well as by 
ICAM-3 itself (Hern~indez-Caselles  et al.,  1993). 
We propose a model for the participation of ICAM-3 in 
leukocyte migration to inflammatory foci. LFA-l-activated 
bearing cells (e.g., antigen-presenting cells) could bind to 
resting T lymphocytes through LFA-1/ICAM-3 interactions 
that could induce mutual cocapping of both molecules that, 
in turn, would reinforce cell stimulation on both cells (Cam- 
panero et al., 1993; Hern~indez-Caselles  et al., 1993).  This 
interaction might be mimicked by the ICAM-3 HP2/19 mAb 
in our in vitro system. Next, activated leukocytes would bind 
to  endothelial  cells  through  LFA-1/ICAM-1  and  VLA-4/ 
VCAM-1 interactions. Leukocytes would spread out on the 
endothelium and the heading uropod, where ICAM-3 would 
be concentrated, would raise from the flattened area of the 
cell, in close contact with the endothelial cell, towards the 
lumen of the vessel. The enormous density of ICAM-3 on 
this structure together with its location in the lumen of the 
vessel, would facilitate the interaction with the LFA-1 on cir- 
culating leukocytes which would be recruited and possibly 
stimulated. 
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